- Details
- Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have had an impact in diagnosing nmCRPC by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA kinetics in...
|
- Details
- Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...
|
- Details
- In this conversation, Alicia Morgans and Farnoosh Nik-Ahd discuss the diagnosis of prostate cancer in transgender women. Dr. Nik-Ahd highlights that despite gender affirmation surgeries, transgender women, who were assigned male at birth, retain their prostates and therefore remain at risk for prostate cancer. Using data collected from the Veterans Health Administration, she discusses the complexi...
|
- Details
- Alicia Morgans is joined by Drs Fred Saad, Charles Ryan, and Tomasz Beer at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland, to discuss holistic treatment of men with prostate cancer who are being treated with ADT. Dr. Ryan discusses the lack of data on the treatment of depression in men on hormone therapy. Dr. Saad discusses the need to be aware of the patien...
|
- Details
- Zach Klaassen joins Alicia Morgans in discussing an underestimated topic of mental health and its effects on patients with genitourinary cancers. Drs. Klaassen and Morgans discuss hypothesis-generating population-level data in this landscape and talk through the importance of supporting these patients and using what Dr. Klaassen refers to as clinical intuition and asking follow-up questions when s...
|
- Details
- Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic castrati...
|
- Details
- Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients achievi...
|
- Details
- Gerhardt Attard joins Alicia Morgans to discuss a combined analysis from two comparisons in the STAMPEDE platform. Dr. Gerhardt Attard presented a combined analysis from the STAMPEDE platform assessing the role of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0...
|
- Details
- Alicia Morgans is joined by Felix Feng to discuss molecular determinants associated with response to apalutamide in patients who have nonmetastatic castration-resistant prostate cancer (nmCRPC). SPARTAN, a phase 3 placebo-controlled study in patients (pts) with nmCRPC, showed that apalutamide plus androgen deprivation therapy (ADT) significantly improves metastasis-free survival compared with plac...
|
- Details
- Importance of early intervention in nmCRPC—A discussion with Karim Fizazi, MD, PhD. Darolutamide, an androgen receptor inhibitor, was developed to improve the safety profile of apalutamide and enzalutamide. It has a distinct structure that offers low penetration of the blood-brain barrier as well as other characteristics with the potential for fewer and less toxic adverse events (AEs). The primary...
|